News & Events
BD Introduces New Systems to Make Diabetes Monitoring and Management Easier, Faster, and Less Painful
|
BD Logic™ Blood Glucose Monitor and BD Latitude™ Diabetes Management System Enable Greater Control and Compliance Franklin Lakes, NJ (January 08, 2003) -- BD (Becton, Dickinson and Company) (NYSE:BDX), the leading provider of insulin delivery systems, has announced today the U.S. availability of two new FDA-cleared blood glucose monitoring products designed to help improve diabetes management. The BD Logic™ Blood Glucose Monitor and the BD Latitude™ Diabetes Management System combine the thinnest lancets available with test strips that require a very small amount of blood and deliver accurate readings in a fast amount of time - only five seconds. No other device offers all of these features in one system.
"Diabetes remains one of the most prevalent health issues in America," said Edward J. Ludwig, Chairman, President and Chief Executive Officer of BD. "Of the 17 million Americans with diabetes, 11 million have been diagnosed with type 1 or type 2 diabetes, and approximately 6 million still remain undiagnosed. At BD, we are committed to developing products and systems such as the BD Logic™ and BD Latitude™ monitors that will help improve diabetes management and the quality of life for those who have this disease." People with diabetes understand the unique challenges of monitoring blood glucose levels. For those who must monitor daily, or even several times a day, the process can be painful and time-consuming. However, accurately and consistently monitoring blood glucose levels is essential to managing the disease and can help prevent such complications as heart and kidney disease, blindness, stroke and amputations. "These new monitors represent a breakthrough in diabetes care," said Dr. Robin S. Goland, director of the Naomi Berrie Diabetes Center at Columbia-Presbyterian Medical Center in New York. "We see many people with diabetes who need to monitor six or more times a day, and this innovation will offer them fast, accurate readings and greater convenience with less pain and less blood." People with diabetes find that the BD Logic Blood Glucose Monitor significantly reduces lancing pain by utilizing BD Ultra-Fine™ 33 Lancets, as compared to the standard 28-gauge version. Accurate results are achieved in only 5 seconds, and with a very small amount of blood - .3 muL - less than a third of most other tests.
In addition, the blood glucose monitors display current readings and have memory capacities of up to 250 blood glucose and 250 insulin records at one time, enabling people with diabetes to maintain accurate monitoring without significant interruption to busy and active lifestyles. "These new monitoring devices can help ensure that 'peaks and valleys' are avoided, thus allowing people with diabetes and their doctors to monitor patterns most effectively and achieve compliance," stated Dr. Goland.
The BD Latitude Diabetes Management System is an all-in-one device that combines this new and efficient blood glucose monitor with an organizer that holds all the necessary supplies for testing and insulin injection.
For more than five decades, BD has been the leader in the development of insulin delivery systems that help enhance injection comfort, making therapy easier and helping to improve lifestyles for people with diabetes.
For more information about diabetes and its treatment, talk to your healthcare provider. To learn more about the BD Logic Blood Glucose Monitor and the BD Latitude Diabetes Management System, visit www.bddiabetes.com.
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2002, BD reported total revenues of $4.033 billion.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in healthcare or other governmental regulation, as well as other factors discussed in this press release and in BD's most recent Form 10-K filed with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.
BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company © 2003 BD
Brands are trademarks of their respective holders.
Contacts:
Charles A. Borgognoni
Michael Roth
Patricia Spinella
|